There’s an idea floating around out there called “young blood” to use donations from young folks to infuse older people to reverse aging. I’m skeptical. Imagine an old man and a teenager sitting side by side, with blood flowing from the kid to the oldster in a stab at anti-aging. Sort of like a one-way […]
Young blood as anti-aging fountain of youth: hype or hope? Read More »
The U.S. Senate just passed a bill that if it becomes law would codify Right-To-Try as a federal law, meaning terminally patients across the U.S. could ask their physicians and drug manufacturers to be given still investigational therapies such as still unproven stem cell therapies in development. The bill’s official name is “The Trickett Wendler
Senate Passes Federal Right-To-Try: Poll on Your Opinion Read More »
Should patients have the Right To Try experimental therapies that could be unsafe and ineffective? What if those patients have a terminal illness and no reasonable prospects of being helpful to conventional medicine? Doesn’t it make perfect sense to let them try a risky approach if they want to do so? On the other hand,
Upcoming Right-To-Try debate: NYU’s Roxland and Goldwater’s Sandefur Read More »
Privacy Notice (note for comment policy scroll down) This privacy notice discloses the privacy practices for The Niche at https://ipscell.com. This privacy notice applies solely to information collected by this website. It will notify you of the following: What personally identifiable information is collected from you through the website, how it is used and with
New FDA Commissioner Dr. Scott Gottlieb, M.D., has in the past touched on stem cells and regenerative medicine therapies in speeches or written comments prior to starting his tenure at the agency. Now that he is Commissioner, he is poised to have direct impact on our field rather quickly and potentially with major changes in
Reading the tea leaves as new FDA commish Gottlieb blogs on regenerative medicine Read More »
2,000 is a big number. As of this week I’ve now published 2,000 posts here on The Niche since I started back in early 2010. I can’t quite believe it myself. To celebrate that milestone, I have revamped The Niche in terms of its organization and style with the help of a very skilled web
The Niche’s 2,000th post: where do we go from here? Read More »
Hans Keirstead is one of the top stem cell scientists in the world who has been doing cutting edge research including on using stem cells to reverse paralysis where he teamed up with super patient advocate Roman Reed (see the two pictured at right), but now he is also running for Congress. How cool is that?
Hans Keirstead interview on his congressional run, how you can help Read More »
ISSCR meeting review By Agnes Soos Amid the hustle and bustle of downtown Boston, nearly four thousand researchers and exhibitors gathered for the 15th Annual ISSCR Meeting. With presentations from over thirty plenary lectures, and dozens of others featured in concurrent sessions and the daily Innovation Showcases, there definitely was no shortage of exciting research
Highlights of ISSCR2017 – A Biomedical Engineer’s Perspective Read More »
The idea of CIRM as a dedicated state stem cell agency was one of the things that got me excited about starting my time as a professor doing research on stem cells in California way back in 2005-2006 on the job hunt. Fast forwarding to today now 11 years later, CIRM is still on the
3 CIRM challenges: search for new prez, funding, & clinical POW! Read More »
Over at the California Stem Cell Report, David Jensen is reporting on some good news from CIRM for California on the stem cell clinical trial front. Stem cell biotechs Asterias and Capricor have stem cell trials supported by 20+ million in CIRM funding each and have been hitting milestones. These trials are progressing and so far have good safety
Upbeat prospects for some California clinical trial efforts from CIRM Read More »